{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fcdk4-6-inhibition-in-breast-cancer-kJOrjNMK","width":444,"version":"1.0","type":"rich","title":"Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/f5d365b6-3090-43fa-a403-5e1760a52a0c/7347-breast-cdk4-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/be637014-9dae-47e9-8192-4f113be9a7aa\" height=\"200\" width=\"100%\" title=\"Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer \" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast based on a live symposium at the American Society of Clinical Oncology 2024 Annual Meeting, 3 experts discuss the role of CDK4/6 inhibitors in the adjuvant and metastatic setting for HR-/HER2- breast cancer."}